Lupus Nephritis: Current Advances and Future Options for Screening and Treatment

Main Article Content

Reena Yaman Krish Relan Mandar Shah Archit Srivastava Sehreen Mumtaz Vikas Majithia

Abstract

Background: Lupus nephritis is one of the most common severe organ manifestations of systemic lupus erythematosus (SLE). Despite the continuing advancement in therapy, up to 30% of patients progress to end-stage renal disease. The clinical manifestations of lupus nephritis are variable and screening all SLE patients for lupus nephritis is imperative. There has been substantial advancement in availability of biomarkers and therapeutic options. This review focuses on epidemiology, early screening, advances in the biomarkers and management of lupus nephritis.


Content:  Lupus nephritis is a devastating consequence of SLE and disproportionately affects the minorities. Inter-ethnic variation in the prevalence and severity of lupus nephritis as well as tolerance and clinical response to various therapeutic regimens for LN has led to variation in screening and treatment of lupus nephritis in SLE patients. Periodic screening of lupus nephritis in patients with SLE is imperative for early detection. Urinalysis and urine protein-to-creatinine ratio are useful screening tests. Quantification can be performed by 24-h urine sample collection for protein. Renal biopsy remains the gold standard for diagnosis of lupus nephritis. Traditional serum biomarkers used to monitor lupus nephritis disease activity and flares include anti-double-stranded DNA antibodies and complement components 3 and 4. New biomarkers for lupus nephritis include anti-C1q and type 1 interferon regulatory genes, urinary monocyte chemoattractant protein 1, neutrophil gelatinase-associated lipocalin, tumor necrosis factor-like inducer of apoptosis, and vascular cell adhesion molecule 1. Therapeutic options that better lead to remission of lupus nephritis, preserve kidney function and reduce the toxicities of concomitant glucocorticoids are unmet needs in lupus nephritis. There are newly approved treatments as well as investigational drugs in the pipeline, including the newer generation calcineurin inhibitors, biologic agents and cellular therapeutic options. The choice of therapy depends on a numberof clinical considerations and should be tailored to individual patient circumstances. Molecular profiling, gene-signature fingerprints and urine proteomic panels might enhance the accuracy of patient stratification for treatment personalization in the future.


Summary: Promising advances have been made in screening and treatment of lupus nephritis. The use of traditional and alternative biomarkers has the potential to identify at risk patients and those having active flare-up but require validation in prospective studies. Renal remission rates in patients receiving standard of care therapy for induction and maintenance treatments have improved but remain low. Further research in newer therapeutic targets for lupus nephritis shows promising results.


Key points


  • The development of biomarkers for early detection and novel therapeutics to improve the efficacy-to-toxicity balance for LN are current unmet needs.

  • New serum and urinary biomarkers for LN can help screen and stratify the patients at risk and those having flare-up of LN.

  • Biologic, belimumab and calcineurin inhibitor, voclosporin are recently approved drugs for the treatment of LN offering potential to provide early and sustained remission in LN.

  • Options to better stratify patients and provide personalized treatment for patients with LN such as molecular profiling and urine proteomic panels are on the horizon.

  • New-generation anti-CD20 biologic agents, type I interferon antagonists, combination of biologics and cellular therapies such as autologous anti-CD19 CAR-T cell show promise for the treatment of LN.

Article Details

How to Cite
YAMAN, Reena et al. Lupus Nephritis: Current Advances and Future Options for Screening and Treatment. Medical Research Archives, [S.l.], v. 13, n. 1, jan. 2025. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/6217>. Date accessed: 10 feb. 2025. doi: https://doi.org/10.18103/mra.v13i1.6217.
Section
Review Articles

References

1. Hocaoǧlu M, Valenzuela-Almada MO, Dabit JY, et al. Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population-Based Study Over Four Decades Using the Lupus Midwest Network. Arthritis Rheumatol. 2023 Apr;75(4):567-573.
2. Fiehn, C.; Hajjar, Y.; Mueller, K.; Waldherr, R.; Ho, A.D.; Andrassy, K. Improved clinical outcome of lupus nephritis during the past decade: Importance of early diagnosis and treatment. Ann. Rheum. Dis. 2003, 62, 435–439.
3. Desai SB, Ahdoot R, Malik F, Obert M, Hanna R. New guidelines and therapeutic updates for the management of lupus nephritis. Curr Opin Nephrol Hypertens. 2024;33(3):344-353. doi:10.1097/MNH.0000000000000969.
4. Smith CD, Cyr M. The History of Lupus Erythematosus. Rheum Dis Clin N Am. 1988;14(1):1-14. doi:10.1016/S0889-857X(21)00942-X.
5. Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64(6):797-808. doi:10.1002/acr.21664.
6. Alarcon GS, McGwin G Jr, Petri M, et al. Baseline characteristics of a multiethnic lupus cohort: PROFILE. Lupus. 2002;11:95–101.
7. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum. 2013 Mar;65(3):753-63. doi: 10.1002/art.37795. PMID: 23203603; PMCID: PMC3733212.
8. Mok CC, Kwok RC, Yip PS. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–2160.
9. Anders HJ, Rovin B. A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 2016; 90:493–501.
10. Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, Cook HT, Fervenza FC, Gibson KL, Glassock RJ, Jayne DRW, Jha V, Liew A, Liu ZH, Mejía-Vilet JM, Nester CM, Radhakrishnan J, Rave EM, Reich HN, Ronco P, Sanders JF, Sethi S, Suzuki Y, Tang SCW, Tesar V, Vivarelli M, Wetzels JFM, Lytvyn L, Craig JC, Tunnicliffe DJ, Howell M, Tonelli MA, Cheung M, Earley A, Floege J. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
11. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz MB, Gladman DD, Kalunian K, Costner M, Werth V, Zoma A, Bernatsky S, Ruiz-Irastorza G, Khamashta M, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Van Vollenhoven R, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim S, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks Jr. AG , Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin Jr. G, Magder LS. Derivation and validation of Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677-2686.
12. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leew B, Bertsias G, Jayne D, Boumpas DT. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020 Jun;79(6):713-723. doi:10.1136/annrheumdis-2020-216924.
13. Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017 May 8;12(5):825-835. doi: 10.2215/CJN.05780616. Epub 2016 Nov 7. PMID: 27821390; PMCID: PMC5477208.
14. Malvar A, Pirruccio P, Alberton V, et al. Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant. 2017;32:1338–1344.
15. Zickert A, Sundelin B, Svenungsson E, et al. Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014;1:e000018.
16. Stokes MB, D’Agati VD. Classification of Lupus Nephritis; Time for a Change? Adv Chronic Kidney Dis. 2019;26(5):323-329. doi:10.1053/j.ackd.2019.06.002.
17. Danchenko N, Satia J, Anthony M. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 2006;15:308–18.
18. Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009;68:234–7.
19. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350–7.
20. Alforaih N, Whittall-Garcia L, Touma Z. A Review of Lupus Nephritis. J Appl Lab Med. 2022;7(6):1450-1467. doi:10.1093/jalm/jfac036.
21. Pons-Estel GJ, Alarcon GS, McGwin G, Danila MI, Zhang J, Bastian HM, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV. Data From a multiethnic US cohort. Arthritis Rheum 2009;61:830–9.
22. Fanouriakis A, Tziolos N, Bertsias G, et al. Update οn the diagnosis and management of systemic lupus erythematosus Annals of the Rheumatic Diseases 2021;80:14-25.
23. Siegel CH, Sammaritano LR. Systemic Lupus Erythematosus: A Review. JAMA. 2024;331(17):1480–1491. doi:10.1001/jama.2024.2315.
24. Gasparotto M, Gatto M, Binda V, Doria A, Moroni G. Lupus nephritis: clinical presentations and outcomes in the 21st century. Rheumatology (Oxford). 2020 Dec 5;59(Suppl5):v39-v51. doi: 10.1093/rheumatology/keaa381. PMID: 33280015; PMCID: PMC7751166.
25. Mahajan A, Amelio J, Gairy K, Kaur G, Levy RA, Roth D, Bass D. Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression. Lupus. 2020 Aug;29(9):1011-1020. doi: 10.1177/0961203320932219. Epub 2020 Jun 22. PMID: 32571142; PMCID: PMC7425376.
26. Hasan B, Fike A, Hasni S. Health disparities in systemic lupus erythematosus-a narrative review. Clin Rheumatol. 2022 Nov;41(11):3299-3311. doi: 10.1007/s10067-022-06268-y. Epub 2022 Jul 31. PMID: 35907971; PMCID: PMC9340727.
27. Suchun Li, Qimei Luo, Yuting Fan, Chen Zhao, Fengxian Huang, Xi Xia, Wei Chen; Clinicopathological Characteristics and Prognosis of Lupus Nephritis Patients with Acute Kidney Injury. Am J Nephrol 12 December 2023; 54 (11-12): 536–545. https://doi.org/10.1159/000533847.
28. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9. PMID: 31974366.
29. Rovin BH, Ayoub IM, Chan TM, Liu ZH, Mejía-Vilet JM, Floege J. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS. Kidney Int. 2024;105(1):S1-S69. doi:10.1016/j.kint.2023.09.002
30. Lupus Clinical Practice Guideline (Accessed October 20, 2024). https://rheumatology.org/lupus-guideline.
31. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288-91. PMID: 11838846.
32. Isenberg, D.A., Rahman, A., Allen, E.B.I.L.A.G., Farewell, V., Akil, M., Bruce, I.N., D’cruz, D., Griffiths, B., Khamashta, M., Maddison, P. and McHugh, N., 2005. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology, 44(7), pp.902-906.
33. Thanou A, Jupe E, Purushothaman M, Niewold TB, Munroe ME. Clinical disease activity and flare in SLE: Current concepts and novel biomarkers. J Autoimmun. 2021;119:102615.
34. Koichiro Ohmura, Which is the best SLE activity index for clinical trials?, Modern Rheumatology, Volume 31, Issue 1, 2 January 2021, Pages 20–28, https://doi.org/10.1080/14397595.2020.1775928.
35. Petri, M., Kasitanon, N., Lee, S.S., Link, K., Magder, L., Bae, S.C., Hanly, J.G., Isenberg, D.A., Nived, O., Sturfelt, G. and Van Vollenhoven, R., 2008. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 58(6), pp.1784-1788.
36. Aljaberi N, Wenderfer SE, Mathur A, Qiu T, Jose S, Merritt A, Rose J, Devarajan P, Huang B, Brunner H. Clinical measurement of lupus nephritis activity is inferior to biomarker-based activity assessment using the renal activity index for lupus nephritis in childhood-onset systemic lupus erythematosus. Lupus Sci Med. 2022 May;9(1):e000631. doi: 10.1136/lupus-2021-000631. PMID: 35568436; PMCID: PMC9109101.
37. Thanou A, Merrill JT. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol. 2014;10(1):23-34. doi:10.1038/nrrheum.2013.145
38. Tselios K, Gladman DD, Urowitz MB. How can we define low disease activity in systemic lupus erythematosus? Semin Arthritis Rheum. 2019 Jun;48(6):1035-1040. doi: 10.1016/j.semarthrit.2018.10.013. Epub 2018 Oct 16. PMID: 30415943.
39. Alduraibi, F.K. and Tsokos, G.C., 2024. Lupus nephritis biomarkers: a critical review. International Journal of Molecular Sciences, 25(2), p.805.
40. Renaudineau, Y., Brooks, W. and Belliere, J., 2023. Lupus nephritis risk factors and biomarkers: An update. International Journal of Molecular Sciences, 24(19), p.14526.
41. Palazzo, L., Lindblom, J., Mohan, C. and Parodis, I., 2022. Current insights on biomarkers in lupus nephritis: a systematic review of the literature. Journal of Clinical Medicine, 11(19), p.5759.
42. Munroe, M.E., Blankenship, D., DeFreese, D., Purushothaman, M., DeJager, W., Macwana, S., Guthridge, J.M., Kamp, S., Redinger, N., Aberle, T. and Chakravarty, E.F., 2023. A flare risk index informed by select immune mediators in systemic lupus erythematosus. Arthritis & rheumatology, 75(5), pp.723-735.
43. Banos A, Bertsias G. Flares in Lupus Nephritis: Risk Factors and Strategies for Their Prevention. Curr Rheumatol Rep. 2023 Oct;25(10):183-191. doi: 10.1007/s11926-023-01109-6. Epub 2023 Jul 15.
44. Sakhi H, Moktefi A, Bouachi K, Audard V, Hénique C, Remy P, Ollero M, El Karoui K. Podocyte Injury in Lupus Nephritis. J Clin Med. 2019 Aug 29;8(9):1340. doi: 10.3390/jcm8091340.
45. Bruschi M, Angeletti A, Prunotto M, Meroni PL, Ghiggeri GM; Zeus consortium; Moroni G, Sinico RA, Franceschini F, Fredi M, Vaglio A, Cavalli A, Scapozza L, Patel JJ, Tan JC, Lo KC, Cavagna L, Petretto A, Pratesi F, Migliorini P, Locatelli F, Pazzola G, Pesce G, Giannese D, Manfredi A, Ramirez GA, Esposito P, Murdaca G, Negrini S, Bui F, Trezzi B, Emmi G, Cavazzana I, Binda V, Fenaroli P, Pisan I, Montecucco C, Santoro D, Scolari F, Mescia F, Volpi S, Mosca M, Tincani A, Ravelli A, Murtas C, Candiano G, Caridi G, La Porta E, Verrina E. A critical view on autoantibodies in lupus nephritis: Concrete knowledge based on evidence. Autoimmun Rev. 2024 May;23(5):103535. doi: 10.1016/j.autrev.2024.103535.
46. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. 2024 Nov 18 (Pending publication).
47. Naomi, I, Maria., Anne, Davidson. (2020). Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nature Reviews Rheumatology, 16(5):255-267. doi: 10.1038/S41584-020-0401-9.
48. Bajema IM, Wilhelmus S, Alpers CE, Bruijn JA, Colvin RB, Cook HT, D’Agati VD, Ferrario F, Haas M, Jennette JC, Joh K, Nast CC, Noël LH, Rijnink EC, Roberts ISD, Seshan SV, Sethi S, Fogo AB. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018 Apr;93(4):789-796. doi: 10.1016/j.kint.2017.11.023.
49. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, Ruiz-Irastorza G, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertsias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajuk G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Czirják L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 Sep;71(9):1400-1412. doi: 10.1002/art.40930.
50. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, Boletis J, Bruce IN, Cervera R, Doria A, Dörner T, Furie RA, Gladman DD, Houssiau FA, Inês LS, Jayne D, Kouloumas M, Kovács L, Mok CC, Morand EF, Moroni G, Mosca M, Mucke J, Mukhtyar CB, Nagy G, Navarra S, Parodis I, Pego-Reigosa JM, Petri M, Pons-Estel BA, Schneider M, Smolen JS, Svenungsson E, Tanaka Y, Tektonidou MG, Teng YO, Tincani A, Vital EM, van Vollenhoven RF, Wincup C, Bertsias G, Boumpas DT. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis. 2024 Jan 2;83(1):15-29. doi: 10.1136/ard-2023-224762.
51. Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD, Marder W, Guyatt G, Branch DW, Buyon J, Christopher-Stine L, Crow-Hercher R, Cush J, Druzin M, Kavanaugh A, Laskin CA, Plante L, Salmon J, Simard J, Somers EC, Steen V, Tedeschi SK, Vinet E, White CW, Yazdany J, Barbhaiya M, Bettendorf B, Eudy A, Jayatilleke A, Shah AA, Sullivan N, Tarter LL, Birru Talabi M, Turgunbaev M, Turner A, D’Anci KE. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020 Apr;72(4):461-488. doi: 10.1002/acr.24130.
52. Frangou E, Anders HJ, Bajema IM, Teng YKO, Malvar A, Rovin BH, Kronbichler A. Immunosuppression Withdrawal in Patients with Lupus Nephritis: When, How, and for Whom Will It Be Safe? J Am Soc Nephrol. 2024 Jul 1;35(7):955-958. doi: 10.1681/ASN.0000000000000365. Epub 2024 Apr 9.
53. Furie R, Petri M, Zamani O. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918–3930. doi: 10.1002/art.30613.
54. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X.
55. Saxena A, Ginzler EM, Gibson K, Satirapoj B, Santillán AEZ, Levchenko O, Navarra S, Atsumi T, Yasuda S, Chavez-Perez NN, Arriens C, Parikh SV, Caster DJ, Birardi V, Randhawa S, Lisk L, Huizinga RB, Teng YKO. Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial. Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657.
56. Furie RA, Aroca G, Cascino MD, Garg JP, Rovin BH, Alvarez A, Fragoso-Loyo H, Zuta-Santillan E, Schindler T, Brunetta P, Looney CM, Hassan I, Malvar A. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2022 Jan;81(1):100-107. doi: 10.1136/annrheumdis-2021-220920.
57. Avasare R, Drexler Y, Caster DJ, Mitrofanova A, Jefferson JA. Management of Lupus Nephritis: New Treatments and Updated Guidelines. Kidney360. 2023 Oct 1;4(10):1503-1511. doi: 10.34067/KID.0000000000000230.
58. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet 2023; 402: 2034–44.
59. Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, Simon D, Kleyer A, Munoz L, Kretschmann S, Kharboutli S, Gary R, Reimann H, Rösler W, Uderhardt S, Bang H, Herrmann M, Ekici AB, Buettner C, Habenicht KM, Winkler TH, Krönke G, Schett G. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med. 2022 Oct;28(10):2124-2132. doi: 10.1038/s41591-022-02017-5.
60. Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, Aigner M, Rothe T, Minopoulou I, Tur C, Knitza J, Kharboutli S, Kretschmann S, Vasova I, Spoerl S, Reimann H, Munoz L, Gerlach RG, Schäfer S, Grieshaber-Bouyer R, Korganow AS, Farge-Bancel D, Mougiakakos D, Bozec A, Winkler T, Krönke G, Mackensen A, Schett G. CD19 CAR T-Cell Therapy in Autoimmune Disease - A Case Series with Follow-up. N Engl J Med. 2024 Feb 22;390(8):687-700. doi: 10.1056/NEJMoa2308917.
61. Figueroa‐Parra G, Cuéllar‐Gutiérrez MC, González‐Treviño M, et al. Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta‐Analysis of the Control Arms of Randomized Controlled Trials. Arthritis Rheumatol. 2024;76(9):1408-1418. doi:10.1002/art.42920
62. Sobhy N, Ezzat Y, Gamal SM, et al. Cumulative pulse methylprednisolone and its relation to disease activity, damage and mortality in systemic lupus erythematosus patients: A post hoc analysis of COMOSLE-EGYPT study. Clin Rheumatol. 2024;43(3):985-992. doi:10.1007/s10067-023-06858-4
63. Solé C, Royo M, Sandoval S, Moliné T, Gabaldón A, Cortés-Hernández J. Precise Targeting of Autoantigen-Specific B Cells in Lupus Nephritis with Chimeric Autoantibody Receptor T Cells. Int J Mol Sci. 2024;25(8):4226. doi:10.3390/ijms25084226
64. So BYF, Yap DYH, Chan TM. MicroRNAs in Lupus Nephritis–Role in Disease Pathogenesis and Clinical Applications. Int J Mol Sci. 2021;22(19):10737. doi:10.3390/ijms221910737